|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cerebrovascular Accident | |||||
| Depression | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Cerebral Infarction | |||||
| Depressive Disorder | |||||
| Stroke | |||||
| 3 | More general conditions related to this trial | ||||
| Behavioral Symptoms | |||||
| Brain Diseases | |||||
| Brain Infarction | |||||
| Brain Ischemia | |||||
| Cardiovascular Diseases | |||||
| Central Nervous System Diseases | |||||
| Cerebrovascular Disorders | |||||
| Mental Disorders | |||||
| Mood Disorders | |||||
| Nervous System Diseases | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| sertraline | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antidepressive Agents | |||||
| Central Nervous System Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Serotonin Agents | |||||
| Serotonin Uptake Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||